SETD6

Across TCGA pan-cancer cohorts, SETD6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SETD6 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SETD6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SETD6 expression acts as an unfavorable survival marker.

HNSC, LUAD, and LSCC are the cancer types where SETD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.456	0.861	.008	10	view →
LUAD	OS	Tertile	All	0.500	0.826	.022	8	view →
LSCC	DFS	Median	II,III,IV	0.187	1.000	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SETD6–HNSC (DFS)

Open the HNSC breakdown →